<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">109866</article-id><article-id pub-id-type="doi">10.7554/eLife.109866</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Breast Cancer</subject></subj-group></article-categories><title-group><article-title>Slowing the growth of drug-resistant tumors</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Yingyi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1020-7964</contrib-id><email>yingyi_zhang@tju.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Yingyi Zhang</bold> is in the School of Disaster and Emergency Medicine, Tianjin University, Tianjin, China and the Tianjin Key Laboratory of Disaster Medicine Technology, Tianjin, China</p></bio></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lu</surname><given-names>Qianying</given-names></name><email>qianying.lu@tju.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Qianying Lu</bold> is in the School of Disaster and Emergency Medicine, Tianjin University, Tianjin, China and the Tianjin Key Laboratory of Disaster Medicine Technology, Tianjin, China</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012tb2g32</institution-id><institution>School of Disaster and Emergency Medicine, Tianjin University</institution></institution-wrap><addr-line><named-content content-type="city">Tianjin</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Tianjin Key Laboratory of Disaster Medicine Technology</institution><addr-line><named-content content-type="city">Tianjin</named-content></addr-line><country>China</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>18</day><month>12</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e109866</elocation-id><permissions><copyright-statement>© 2025, Zhang and Lu</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhang and Lu</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-109866-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.104545" id="ra1"/><abstract><p>Using drugs that inhibit enzymes called CDK4/6 and CDK2 extends the G1 phase of the cell cycle and helps to slow the growth of drug-resistant breast cancer.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cyclin dependent kinase</kwd><kwd>breast cancer</kwd><kwd>targeted therapy</kwd><kwd>drug resistance</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Using drugs that inhibit enzymes called CDK4/6 and CDK2 extends the G1 phase of the cell cycle and helps to slow the growth of drug-resistant breast cancer.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Armand J, Kim S, Kim K, Son E, Kim M, Kalinsky K, Yang HW. 2025. Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. <italic>eLife</italic> <bold>14</bold>:RP104545. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.104545">10.7554/eLife.104545</ext-link>.</p></boxed-text><p>Cancer treatments have seen significant advancements in recent decades, but resistance to therapies – even after an initial response to treatment – remains a major challenge (<xref ref-type="bibr" rid="bib7">Sung et al., 2021</xref>). For example, metastatic breast cancer is one of the leading causes of cancer-related mortality in women, and around 30% of patients develop resistance within two years of initial treatment (<xref ref-type="bibr" rid="bib6">O’Leary et al., 2018</xref>; <xref ref-type="bibr" rid="bib2">Goel et al., 2018</xref>).</p><p>A key dysregulation in breast cancer involves the overactivation of certain proteins that drive cell proliferation. In healthy cells, division happens through tightly regulated phases during which DNA is duplicated before the cell splits. The G1 phase, in particular, serves as a checkpoint before DNA replication begins. Enzymes called CDK4 and CDK6 control how quickly cells grow and divide by inactivating (through phosphorylation) the retinoblastoma protein (Rb): this is a tumor suppressor that normally restrains progression through the cell cycle. This inactivation triggers the release of E2Fs, a group of transcription factors that activate genes needed for DNA replication, and promotes entry into the S phase, where DNA replication occurs. At this stage, CDK2 activity becomes progressively dominant over CDK4/6, enabling full transition into the S phase and ensuring DNA replication proceeds correctly.</p><p>In hormone-driven breast cancer, CDK4 and CDK6 are often overactive. Despite the use of drugs that inhibit these enzymes (<xref ref-type="bibr" rid="bib3">Johnston et al., 2020</xref>), some tumors can resist treatment by activating CDK2: this suggests that targeting both CDK4/6 and CDK2 may be necessary to overcome resistance. Now, in eLife, Hee Won Yang and colleagues – including Jessica Armand as first author – report that tumor resistance depends on multiple factors (<xref ref-type="bibr" rid="bib1">Armand et al., 2025</xref>).</p><p>The researchers, who are based at Columbia University and Emory University, studied hormone-driven and triple-negative breast cancer cell lines. All cells had an intact Rb/E2F pathway and were continually exposed to CDK4/6 inhibitors for over a month to induce drug resistance. After resistance emerged, some cells were taken off the treatment, while others continued to receive the inhibitors.</p><p>The results showed that cells kept on the treatment grew significantly more slowly than those taken off it, indicating that even resistant cells can remain partially sensitive to CDK4/6 inhibitors. More detailed analyses revealed that treated resistant cells stayed longer in the G1 phase and divided more slowly. They also showed reduced E2F activity and weaker Rb phosphorylation. With less phosphorylation, Rb remained active, and cells were halted in the G1 phase. Adding a CDK2 inhibitor reinforced this effect. Conversely, overexpressing a protein called Cyclin E, which works with CDK2 to push cells into the S phase even when CDK4/6 is blocked (<xref ref-type="bibr" rid="bib5">Kim et al., 2025</xref>), weakened the inhibitor’s impact. These findings indicate that CDK2 helps drive the cell cycle forward even when CDK4/6 is compromised.</p><p>The study by Armand et al. changes how we think about drug resistance and suggests that resistant tumors might respond to treatment, but not as strongly as non-resistant tumors. Continuing treatment with CDK4/6 inhibitors could therefore help slow down cell division, especially when combined with CDK2 inhibitors. Rather than discontinuing treatment once resistance develops, reinforcing it may thus be a new clinical strategy. This may help explain why some trials have observed benefits from continuing CDK4/6 inhibitors (<xref ref-type="bibr" rid="bib4">Kim et al., 2023</xref>). The results also highlight the need to target multiple points in the cell cycle: instead of focusing on a single enzyme, combination therapy may work better.</p><p>However, more work is needed to test the effectiveness and safety of this approach in patients. Tumors with mutations in the gene for Rb may not benefit from this strategy, and it is still unclear whether endocrine therapy may influence or modify responses to dual inhibition of CDK2 and CDK4/6. To identify which tumors will respond, more reliable biomarkers are needed (<xref ref-type="bibr" rid="bib8">Zhang et al., 2023</xref>). Future research should explore how to personalize therapy based on each tumor’s biology.</p><p>Overall, these findings open new directions for both research and treatment. They highlight that even a modest slowdown of the cell cycle can have meaningful therapeutic effects, and in the context of drug resistance, delaying progression may offer a valuable advantage.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armand</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Son</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Kalinsky</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer</article-title><source>eLife</source><volume>14</volume><elocation-id>RP104545</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.104545</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>DeCristo</surname><given-names>MJ</given-names></name><name><surname>McAllister</surname><given-names>SS</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CDK4/6 inhibition in cancer: beyond cell cycle arrest</article-title><source>Trends in Cell Biology</source><volume>28</volume><fpage>911</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.07.002</pub-id><pub-id pub-id-type="pmid">30061045</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>SRD</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Hegg</surname><given-names>R</given-names></name><name><surname>Toi</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name><name><surname>Zhang</surname><given-names>QY</given-names></name><name><surname>Martinez Rodriguez</surname><given-names>JL</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>E</given-names></name><name><surname>Sohn</surname><given-names>J</given-names></name><name><surname>Guarneri</surname><given-names>V</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Boyle</surname><given-names>F</given-names></name><name><surname>Neven</surname><given-names>P</given-names></name><name><surname>Cortés</surname><given-names>J</given-names></name><name><surname>Huober</surname><given-names>J</given-names></name><name><surname>Wardley</surname><given-names>A</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name><name><surname>Cicin</surname><given-names>I</given-names></name><name><surname>Smith</surname><given-names>IC</given-names></name><name><surname>Frenzel</surname><given-names>M</given-names></name><name><surname>Headley</surname><given-names>D</given-names></name><name><surname>Wei</surname><given-names>R</given-names></name><name><surname>San Antonio</surname><given-names>B</given-names></name><name><surname>Hulstijn</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>O’Shaughnessy</surname><given-names>J</given-names></name><name><surname>Rastogi</surname><given-names>P</given-names></name><collab>monarchE Committee Members and Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)</article-title><source>Journal of Clinical Oncology</source><volume>38</volume><fpage>3987</fpage><lpage>3998</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.02514</pub-id><pub-id pub-id-type="pmid">32954927</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Armand</surname><given-names>J</given-names></name><name><surname>Safonov</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Soni</surname><given-names>RK</given-names></name><name><surname>Schwartz</surname><given-names>G</given-names></name><name><surname>McGuinness</surname><given-names>JE</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Razavi</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Chandarlapaty</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer</article-title><source>Cell Reports</source><volume>42</volume><elocation-id>113198</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2023.113198</pub-id><pub-id pub-id-type="pmid">37865915</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Jeong</surname><given-names>K</given-names></name><name><surname>Ozmen</surname><given-names>TY</given-names></name><name><surname>Ozmen</surname><given-names>F</given-names></name><name><surname>Rames</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Jameson</surname><given-names>N</given-names></name><name><surname>de Jong</surname><given-names>PR</given-names></name><name><surname>Yea</surname><given-names>S</given-names></name><name><surname>Harford</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Mathews</surname><given-names>CA</given-names></name><name><surname>Doroshow</surname><given-names>DB</given-names></name><name><surname>Charles</surname><given-names>VJ</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Samatar</surname><given-names>AA</given-names></name><name><surname>Jubb</surname><given-names>A</given-names></name><name><surname>Bunker</surname><given-names>KD</given-names></name><name><surname>Blackwell</surname><given-names>K</given-names></name><name><surname>Simpkins</surname><given-names>F</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Harismendy</surname><given-names>O</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Lackner</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers</article-title><source>NPJ Precision Oncology</source><volume>9</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1038/s41698-024-00787-4</pub-id><pub-id pub-id-type="pmid">39755818</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Leary</surname><given-names>B</given-names></name><name><surname>Cutts</surname><given-names>RJ</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hrebien</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Fenwick</surname><given-names>K</given-names></name><name><surname>André</surname><given-names>F</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Garcia-Murillas</surname><given-names>I</given-names></name><name><surname>Cristofanilli</surname><given-names>M</given-names></name><name><surname>Huang Bartlett</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>1390</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0264</pub-id><pub-id pub-id-type="pmid">30206110</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA</source><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>7847</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-43716-y</pub-id></element-citation></ref></ref-list></back></article>